Literature DB >> 30213460

Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.

Emily B Heikamp1, Ching-Hon Pui2.   

Abstract

Entities:  

Keywords:  cytotoxic chemotherapy; immunotherapy; minimal residual disease; next-generation sequencing; precision medicine; targeted therapy

Mesh：

Substances：

Year:  2018        PMID： 30213460      PMCID： PMC6261438          DOI： 10.1016/j.jpeds.2018.07.039

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  121 in total

1.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

2.  Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.

Authors:  Guillermo Gervasini; Silvia G de Murillo; Mercedes Jiménez; María D de la Maya; Jose M Vagace
Journal:  J Pediatr Hematol Oncol       Date:  2017-11       Impact factor: 1.289

3.  Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.

Authors:  Ronald W Stam; Pauline Schneider; Paola de Lorenzo; Maria G Valsecchi; Monique L den Boer; Rob Pieters
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

4.  A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.

Authors:  Sohela Shah; Kasmintan A Schrader; Esmé Waanders; Andrew E Timms; Joseph Vijai; Cornelius Miething; John T Sandlund; Marshall S Horwitz; Charles G Mullighan; Kenneth Offit; Jeremy Wechsler; Jun Yang; James Hayes; Robert J Klein; Jinghui Zhang; Lei Wei; Gang Wu; Michael Rusch; Panduka Nagahawatte; Jing Ma; Shann-Ching Chen; Guangchun Song; Jinjun Cheng; Paul Meyers; Deepa Bhojwani; Suresh Jhanwar; Peter Maslak; Martin Fleisher; Jason Littman; Lily Offit; Rohini Rau-Murthy; Megan Harlan Fleischut; Marina Corines; Rajmohan Murali; Xiaoni Gao; Christopher Manschreck; Thomas Kitzing; Vundavalli V Murty; Susana Raimondi; Roland P Kuiper; Annet Simons; Joshua D Schiffman; Kenan Onel; Sharon E Plon; David Wheeler; Deborah Ritter; David S Ziegler; Kathy Tucker; Rosemary Sutton; Georgia Chenevix-Trench; Jun Li; David G Huntsman; Samantha Hansford; Janine Senz; Thomas Walsh; Ming Lee; Christopher N Hahn; Kathryn Roberts; Mary-Claire King; Sarah M Lo; Ross L Levine; Agnes Viale; Nicholas D Socci; Katherine L Nathanson; Hamish S Scott; Mark Daly; Steven M Lipkin; Scott W Lowe; James R Downing; David Altshuler
Journal:  Nat Genet       Date:  2013-09-08       Impact factor: 38.330

5.  Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Authors:  Martin Schrappe; Kirsten Bleckmann; Martin Zimmermann; Andrea Biondi; Anja Möricke; Franco Locatelli; Gunnar Cario; Carmelo Rizzari; Andishe Attarbaschi; Maria Grazia Valsecchi; Claus R Bartram; Elena Barisone; Felix Niggli; Charlotte Niemeyer; Anna Maria Testi; Georg Mann; Ottavio Ziino; Beat Schäfer; Renate Panzer-Grümayer; Rita Beier; Rosanna Parasole; Gudrun Göhring; Wolf-Dieter Ludwig; Fiorina Casale; Paul-Gerhardt Schlegel; Giuseppe Basso; Valentino Conter
Journal:  J Clin Oncol       Date:  2017-11-17       Impact factor: 44.544

6.  Racial and ethnic differences in survival of children with acute lymphoblastic leukemia.

Authors:  Smita Bhatia; Harland N Sather; Nyla A Heerema; Michael E Trigg; Paul S Gaynon; Leslie L Robison
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

7.  Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Arnaud Petit; Amélie Trinquand; Sylvie Chevret; Paola Ballerini; Jean-Michel Cayuela; Nathalie Grardel; Aurore Touzart; Benoit Brethon; Hélène Lapillonne; Claudine Schmitt; Sandrine Thouvenin; Gerard Michel; Claude Preudhomme; Jean Soulier; Judith Landman-Parker; Guy Leverger; Elizabeth Macintyre; André Baruchel; Vahid Asnafi
Journal:  Blood       Date:  2017-10-19       Impact factor: 22.113

8.  Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Authors:  Andrew E Place; Kristen E Stevenson; Lynda M Vrooman; Marian H Harris; Sarah K Hunt; Jane E O'Brien; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Steven E Lipshultz; Jeffery L Kutok; Traci M Blonquist; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  Lancet Oncol       Date:  2015-11-06       Impact factor: 41.316

Review 9.  Global efforts toward the cure of childhood acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Jun J Yang; Nickhill Bhakta; Carlos Rodriguez-Galindo
Journal:  Lancet Child Adolesc Health       Date:  2018-03-30

10.  Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.

Authors:  Julia A Meyer; Jinhua Wang; Laura E Hogan; Jun J Yang; Smita Dandekar; Jay P Patel; Zuojian Tang; Paul Zumbo; Sheng Li; Jiri Zavadil; Ross L Levine; Timothy Cardozo; Stephen P Hunger; Elizabeth A Raetz; William E Evans; Debra J Morrison; Christopher E Mason; William L Carroll
Journal:  Nat Genet       Date:  2013-02-03       Impact factor: 38.330
View more
  12 in total

Review 1.  The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead.

Authors:  William E Evans; Ching-Hon Pui; Jun J Yang
Journal:  Clin Pharmacol Ther       Date:  2019-11-14       Impact factor: 6.875

2.  Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse.

Authors:  Xinyu Wan; Xiaomin Yang; Fan Yang; Tianyi Wang; Lixia Ding; Lili Song; Yan Miao; Xiang Wang; Yani Ma; Chengjuan Luo; Jingyan Tang; Longjun Gu; Jing Chen; Yanjing Tang; Jun Lu; Benshang Li
Journal:  Cancer Res Treat       Date:  2021-09-17       Impact factor: 5.036

Review 3.  Integrating evolutionary dynamics into cancer therapy.

Authors:  Robert A Gatenby; Joel S Brown
Journal:  Nat Rev Clin Oncol       Date:  2020-07-22       Impact factor: 66.675

Review 4.  Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.

Authors:  Valentin Barsan; Sneha Ramakrishna; Kara L Davis
Journal:  Curr Oncol Rep       Date:  2020-01-29       Impact factor: 5.075

Review 5.  Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation.

Authors:  In-Suk Kim
Journal:  Blood Res       Date:  2020-07-31

6.  High Expression of Interleukin-3 Receptor Alpha Chain (CD123) Predicts Favorable Outcome in Pediatric B-Cell Acute Lymphoblastic Leukemia Lacking Prognosis-Defining Genomic Aberrations.

Authors:  Zhiheng Li; Xinran Chu; Li Gao; Jing Ling; Peifang Xiao; Jun Lu; Yi Wang; Hailong He; Jianqin Li; Yixin Hu; Jie Li; Jian Pan; Sheng Xiao; Shaoyan Hu
Journal:  Front Oncol       Date:  2021-03-16       Impact factor: 6.244

7.  Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.

Authors:  Cara E Toscan; Duohui Jing; Chelsea Mayoh; Richard B Lock
Journal:  Br J Cancer       Date:  2020-04-03       Impact factor: 7.640

8.  Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles.

Authors:  Lixian Oh; Pierre Hainaut; Sandrine Blanchet; Hany Ariffin
Journal:  BMC Cancer       Date:  2020-02-10       Impact factor: 4.430

9.  Analysis of the Global Burden of Disease study highlights the trends in death and disability-adjusted life years of leukemia from 1990 to 2017.

Authors:  Zejin Ou; Danfeng Yu; Yuanhao Liang; Wenqiao He; Yongzhi Li; Minyi Zhang; Fangfei You; Huan He; Qing Chen
Journal:  Cancer Commun (Lond)       Date:  2020-09-16

10.  Random survival forest model identifies novel biomarkers of event-free survival in high-risk pediatric acute lymphoblastic leukemia.

Authors:  Zachary S Bohannan; Frederick Coffman; Antonina Mitrofanova
Journal:  Comput Struct Biotechnol J       Date:  2022-01-06       Impact factor: 6.155
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.